Biora Therapeutics, Inc. (BIOR)

Market Cap	36.76M
Revenue (ttm)	726,000
Net Income (ttm)	-117.31M
Shares Out	9.10M
EPS (ttm)	-14.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	495,361
Open	3.94
Previous Close	3.92
Day's Range	3.86 - 4.30
52-Week Range	1.95 - 52.75
Beta	1.06
Analysts	Buy
Price Target	84.15 (+1,977.78%)
Earnings Date	Mar 27, 2023

About BIOR

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 124
• Stock Exchange: NASDAQ
• Ticker Symbol: BIOR

Financial Performance

In 2021, BIOR's revenue was $1.25 million, an increase of 669.75% compared to the previous year's $162,000. Losses were -$247.41 million, 28.3% more than in 2020.

Analyst Forecast

According to 8 analysts, the average rating for BIOR stock is "Buy." The 12-month stock price forecast is $84.15, which is an increase of 1,977.78% from the latest price.

Price Target

$84.15

(1,977.78% upside)

Analyst Consensus: Buy